JNCE News and Press, Jounce Therapeutics Inc. From 11/04/21

Jounce Therapeutics (NASDAQ:JNCE): Q3 GAAP EPS of -$0.59 misses by $0.15. Ended the quarter with $249.0 million in cash, cash equivalents and investments. Press Release For further details see: Jounce Therapeutics EPS misses by $0.15

- Commenced enrollment in tumor-specific monotherapy and pimivalimab combination expansion cohorts of INNATE trial of JTX-8064 - - Ended the quarter with $249.0 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at...

ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...

Jounce Therapeutics (NASDAQ:JNCE) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.42 (+42.5% Y/Y) and the consensus Revenue Estimate is $6.48M Over the last 3 months, EPS estimates have seen 3 upward revisions and 2...

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2021 financial results...

- Enrollment initiated in tumor-specific monotherapy and pimivalimab combination expansion cohorts – - Monotherapy and pimivalimab combination dose escalation enrollment completed - CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDA...

NanoViricides (NYSE:NNVC) +45%. Viridian Therapeutics VRDN +28% secures $85M capital raise ReWalk Robotics (NASDAQ:RWLK) +22%. BIO-key International (NASDAQ:BKYI) +17%. Sino-Global Shipping America (NASDAQ:SINO) +15% and Hebei Yanghuai Technology restructure mining server agree...

Gainers: ABCL +19.8%. TCRR +7.4%. ATAI +6.7%. FANG +4.9%. VCYT +4.7%. Losers: KYMR -7.6%. GRTS -5.1%. JNCE -4.4%. GDS -3.4%. AMTX -3.3%. For further details see: ABCL, TCRR, KYMR and GRTS among after hours movers

CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Co...

Gainers: BELLUS Health (NASDAQ:BLU) +26%, aTyr Pharma (NASDAQ:LIFE) +22%, Jounce Therapeutics (NASDAQ:JNCE) +14%, NanoViricides (NYSE:NNVC) +12%, Matinas BioPharma (NYSE:MTNB) +12%. Losers: Virpax Pharmaceuticals (NASDAQ:VRPX) -37%, RedHill Bi...